Complete remission after combination chemotherapy for stage IV gastric cancer with peritoneal dissemination and liver metastases: Case report

Annals of Cancer Research and Therapy

Volumn 11, Issue 1-2, 2003, Pages 169-181

  Mukai, Masaya ^a   Hinoki, Tomoya ^a   Tajima, Takayuki ^a   Nakasaki, Hisao ^a   Sato, Shinkichi ^a   Okamoto, Yuuichi ^b   Ogoshi, Kyoji ^b   Makuuchi, Hiroyasu ^b  

^a TOKAI UNIVERSITY OISO HOSPITAL   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 FU; CDDP; Gastric cancer; Leucovorin; Liver metastasis; Peritoneal dissemination; TS 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; ANTINEOPLASTIC AGENT; BARIUM; CISPLATIN; CONTRAST MEDIUM; FLUOROURACIL; FOLINIC ACID; INSULIN; OTERACIL; TEGAFUR; TS 1; UNCLASSIFIED DRUG;

ADULT; ALOPECIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SIZE; CANCER STAGING; CASE REPORT; DIARRHEA; GASTROSCOPY; HISTOPATHOLOGY; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; ILEUS; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER METASTASIS; LOW DRUG DOSE; LYMPH NODE METASTASIS; MALE; MUCINOUS CARCINOMA; OMENTUM; OUTPATIENT; PERITONEUM METASTASIS; POSTOPERATIVE PERIOD; RECURRENT DISEASE; SKIN PIGMENTATION; STOMACH CANCER; STOMACH DISEASE; THROMBOCYTOPENIA; TOTAL STOMACH RESECTION; WEIGHT REDUCTION;

EID: 5044231550     PISSN: 13446835     EISSN: None     Source Type: Journal    
DOI: 10.4993/acrt1992.11.169     Document Type: Article

References (20)

1. Chen J-S, Liu H-E, Wang C-H, Yang T-S, Wang H-M, Liau C-T, Chang W-C, and Lin Y-C. (1999). Weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with advanced gastric cancer. Anticancer Drugs 10: 355-359.
2. Cohn J, Tester W, Desai A, Desai A, Levick S, and Andreas J. (1998). Continuous infusion 5-FU and weekly low dose cisplatin (CDDP) in metastatic gastrointestinal malignancies. Proc Am Soc Clin Oncol 7: 115.
3. Enjoji A and the Nagasaki Digestive Organ Cancer Chemotherapy Study Group. (2002). Combination chemotherapy of 5-fluorouracil and low-dose cisplatin in advanced and recurrent gastric cancer: a multicenter retrospective study in Nagasaki, Japan. Anticancer Res 22: 1135-1140.
4. Hsu C-H, Yeh k-H, Chen L-T, Liu JM, Jan C-M, Lin J-T, Chen Y-C, and Cheng A-L. (1997). Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers. Oncology 54: 275-280.
5. Iwamoto S, Kimoto M, Mure T, Onuma E, Yamamoto Y, Iki K, Yoshida K, Tadaoka Y, Majima T, Kawasaki S, Kubozoe T, and Tsunoda T. (1998). Sequential chemotherapy with methotrexate and 5-fluorouracil for advanced gastric cancer. Jpn J Cancer Chemother 25: 541-546.
6. Koizumi W, Kurihara M, Nakano S, Hasagawa K, for the S-1 Cooperative Gastric Cancer Study Group. (2000). Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58: 191-197.
7. Kondo K, Murase M, Yokoyama Y, Kato J, Hibi K, Kasai Y, Akiyama S, Ito K, and Takagi H. (1996). Neoadjuvant chemotherapy in high-grade advanced gastric cancer with protracted infusion of 5-fluorouracil and consecutive low-dose cisplatin. Jpn J Cancer Chemother 23: 1299-1303 (in Japanese with English abstract).
8. Konishi T, Hiraishi M, Mafune K, Miyama T, Hirata T, Mori K, Nishina H, and Idezuki Y. (1994). Therapeutic efficacy and toxicity of sequential methotrexate and 5-fluorouracil in gastric cancer. Anticancer Res 14: 1277-1280.
9. Kim R, Tanabe K, Inoue H, and Toge T. (2002). Mechanisms of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma. Int J Oncol 20: 549-555.
10. Kim R, Murakami S, Ohi Y, Inoue H, Yoshida K, and Toge T. (1999). A phase II trial of low dose administration of 5-fluorouracil and cisplatin in patients with advanced and recurrent gastric cancer. Int J Oncol 15: 921-926.
11. Lacave AJ, Barón FJ, Antón LM, Estrada E, De Sande LMG, Palacio I, Esteban E, Gracia JM, Buesa JM, Fernández; OA, and Barón MG. (1991). Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol 2: 751-754.
12. Mori N, Masaki Y, Etoh R, Yamamoto K, Tangoku A, and Oka M. (1999). A case of advanced gastric cancer of stage IVb with long-term survival by combination chemotherapy with 5-FU and low-dose CDDP. Jpn J Clin Surg 60: 2879-2883 (in Japanese with English abstract).
13. Mukai M, Moriya H, Himeno S, Oida Y, Mukoyama S, Nishi T, Nakasaki H, Sato S, and Makuuchi H. (2001). Efficacy of oral UFT plus leucovorin therapy for colon cancer with ovarian and multiple liver metastases: report of two cases. Oncol Rep 8: 1079-1083.
14. Ogawara T, Maki A, Okazaki M, Kijima Y, Kamita N, Sekikawa T, and Matsumoto Y. (1999). Prolongation of the survival of gastric cancer patients with para-aortic lymph node metastasis through combination therapy with continuous 5-fluorouracil and low-dose (daily) cisplatin. Jpn J Clin Surg 60: 1449-1453 (in Japanese with English abstract).
15. Ohtsu A, Yoshida S, and Saito D. (1991). An early phase II study of 5-fluorouracil combined with cis-platinum as a second line chemotherapy against metastatic gastric cancer. Jpn J Clin Oncol 21: 120-124.
16. Pérez JE, Lacava JA, Dominguez ME, Rodriguez R, Barbieri MR, OrtizEH, Acuña LAR, Langhi MJ, Acuña JMR, Vallejo CT, Leone BA, Machiavelli MR, and Romero AO. (1998). Biochemical modulation of 5-fluorouracil by methotrexate in patients with advanced gastric carcinoma. Am J Clin Oncol 21: 452-457.
17. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, and Taguchi T. (1998). Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M Tegafur-0.4 M Gimestat-1 M Otastat Potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720.
18. Shinkai K, Kida H, Hisano H, Shibasaki S, Yano K and Nomura M. (1999). Treatment with 5-FU modulated by low-dose CDDP for advanced cancer and recurrence with metastasis. Jpn J Cancer Chemother 26: 329-332 (in Japanese with English abstract).
19. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, Taguchi T, and the S-1 Gastrointestinal Cancer Study Group. (1999). An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 57:202-210.
20. Terashima M, Irinoda T, Kawamura H, Takagane A, Abe K, Oyama K, Fujiwara H, Saito K, and Gotoh M. (2003). Intermittent FLDP: 24-h infusion of 5-FU on day 1,3 and 5 combined with low-dose cisplatin on days 1-5 for gastric cancer, and its pharmacologic and kinetic rationale. Cancer Chemother Pharmacol 51: 240-246.